97205 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells Stomach, Intestines
Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
#302Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
#303Anti-PD-L1 antibodies, compositions and articles of manufacture
#304ANTIBODY DRUG CONJUGATES
#305Combination of CD95/CD95L inhibition and Cancer Immunotherapy
#306Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
#307β-glucan methods and compositions that affect the tumor microenvironment
#308Antibodies specifically binding to HER3
#309Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist
#310Anti-malignant tumor agent
#311Anti-EGFR antibodies and antibody drug conjugates
#312Monoclonal antibody against human PrPc and use thereof
#313Therapeutic drug for malignant tumors
#314Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin
#315Endoglin antibodies
#316Humanized monoclonal antibodies and methods of use
#317Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
#318Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors
#319Mutated antibody of fully humanized HER2 antibody, and encoding gene and use thereof
#320Antibody therapeutics that bind CD147
#321Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#322Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#323Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#324Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#325Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
#326Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#327Method for treating cancer with an activated T lymphocyte that selectively recognizes a cancer cell consisting of specific peptide
#328Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#329Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#330Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
#331(Anti-HER2 antibody)-drug conjugate
#332ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER
#333Immunoconjugates with an intracellularly-cleavable linkage
#334METHODS OF ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
#335Immunoactivating antigen-binding molecule
#336Antibody therapeutics that bind LAG3
#337COMBINATION THERAPY COMPRISING ANTI-ANGIOGENESIS AGENTS AND OX40 BINDING AGONISTS
#338ANTI-NOTCH3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
#339PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS
#340Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
#341PROTEINS COMPRISING AMINO-TERMINAL PROXIMAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND CELL-TARGETING IMMUNOGLOBULIN-TYPE BINDING REGIONS
#342Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
#343Fc-ENHANCED ANTI-WT1/HLA ANTIBODY
#344ANTI-MET IN COMBINATION WITH ANTI-VEGFR2 ANTIBODIES THERAPY FOR CANCER
#345Use of pegylated IL-10 to treat cancer
#346Compositions and Methods for Diagnosing and Treating Cancer
#347Recombinant vaccine strains and methods of using the same in cancer immunotherapy
#348Polynucleotides encoding VEGF/DLL4 binding agents
#349DISEASE THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND T CELLS (CAR-T) OR NK CELLS (CAR-NK) EXPRESSING CAR CONSTRUCTS
#350Cancer therapy using CLDN6 target-directed antibodies in vivo
#351Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
#352Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
#353Anti-mesothelin binding proteins
#354Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
#355Peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
#356Anti-HER2 antibody-drug conjugate
#357Anti-human TROP-2 antibody having an antitumor activity in vivo
#358Antibodies against claudin 18.2 useful in cancer diagnosis
#359Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
#360Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody
#361Targeting CLPTM1L for treatment and prevention of cancer
#362Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#363DCLK1 short form specific binding agents
#364Antigen binding proteins that bind ErbB3
#365METHODS OF TREATING PATIENTS HAVING MUTATIONS IN THE EXTRACELLULAR DOMAIN OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH A COMBINATION OF THREE FULLY HUMAN MONOCLONAL ANTI-EGFR ANTIBODIES
#366Treatment with anti-VEGF antibodies
#367Anti-HER2 antibody and conjugate thereof
#368COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY
#369TREATMENT WITH ANTI-VEGF ANTIBODIES
#370Antibody-SN-38 immunoconjugates with a CL2A linker
#371Anti-TROP2 antibody-drug conjugate
#372Pharmaceutical composition for treatment and/or prevention of cancer
#373Antibodies
#374Anti-S100A7 antibodies for the treatment and diagnosis of cancer
#375Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
#376Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof
#377Antibody specific to the AIMP2-DX2
#378Antibodies reactive with B7-H3 and uses thereof
#379TEM8 antibodies and their use in treatment and detection of tumors
#380Glycans as functional cancer targets and antibodies thereto
#381Conjugated antibodies against LY75 for the treatment of cancer
#382Antibodies specific for TROP-2 and their uses
#383Antibody-SN-38 immunoconjugates with a CL2A linker
#384TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR PROTEIN
#385NUCLEIC ACID ENCODING ANTI-PD-L1 ANTIBODIES
#386Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof
#387Immunoconjugates with an intracellularly-cleavable linkage
#388COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND TLR9 AGONIST
#389Single-chain variable fragment anti-CD133 antibodies and uses thereof
#390Targeting of podoplanin with lectin for use in the prevention and treatment of cancer
#391Methods of manipulating phagocytosis mediated by CD47
#392Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#393Monoclonal antibodies against claudin-18 for treatment of cancer
#394Humanized monoclonal antibodies and methods of use
#395Methods of manipulating phagocytosis mediated by CD47
#396NOVEL ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER
#397Methods of manipulating phagocytosis mediated by CD47
#398Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof
#399PROTEIN
#400Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
#401Binding molecules specific for HER3 and uses thereof
#402Cancer stem cell-specific molecule
#403Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to G protein-coupled receptor 49 (GPR49)
#404Anti-claudin 1 antibodies for use in the treatment of colorectal cancer
#405Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
#406Selectin ligands useful in the diagnosis and treatment of cancer
#407Antibodies against CD73
#408RNA-CODED ANTIBODY
#409Anti-ErbB3 antibodies and uses thereof
#410COLON DISEASE TARGETS AND USES THEREOF
#411Tumor marker, monoclonal antibodies and methods of use thereof
#412Tubulysin analogs and methods of making and use
#413Hybridoma clones, monoclonal antibodies, and methods of use
#414Antibodies that bind to Jagged 1
#415Antibody molecules to PD-L1 and uses thereof
#416VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS
#417Method for determining prognosis of cancer
#418Compositions and methods for treatment and detection of cancers
#419Methods for enhancing anti-tumor antibody therapy
#420USE OF THERAPEUTIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCER
#421Immunoconjugates with an intracellularly-cleavable linkage
#422Antibodies to a non-ligand binding region of at least two NOTCH receptors
#423METHODS OF PREDICTING RESPONSIVENESS OF A CANCER TO AN AGENT AND METHODS OF DETERMINING A PROGNOSIS FOR A CANCER PATIENT
#424Methods for manipulating phagocytosis mediated by CD47
#425Methods for manipulating phagocytosis mediated by CD47
#426Anti-RSPO2 antibodies and uses thereof
#427Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#428Methods and compositions for screening and detecting biomarkers
#429Anti-OX40 antibodies and methods of use
#430Methods for cancer management targeting Co-029
#431Antibodies to non-functional P2X7 receptor
#432Prodefensin-A6 assay method for the in vitro diagnosis of colorectal cancer
#433Monoclonal antibodies against claudin-18 for treatment of cancer
#434Monoclonal antibodies against claudin-18 for treatment of cancer
#435Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#436Biomarker TFF1 for predicting effect of C-MET inhibitor
#437THERAPEUTIC AND DIAGNOSTIC TARGET
#438Antibody specifically binding to ANG2 and use thereof
#439Immunoconjugates with an intracellularly-cleavable linkage
#440Multifunctional antibodies binding to EGFR and MET
#441Immunoconjugates with an intracellularly-cleavable linkage
#442Immunoconjugates with an intracellularly-cleavable linkage
#443Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
#444Antibodies against Claudin 18.2 useful in cancer diagnosis
#445Antibody against transporter and use thereof
#446Antibodies to tumor endothelial marker 7R
#447DUAL FUNCTION MARKERS FOR DIAGNOSTICS AND THERAPEUTICS FOR UPPER GASTROINTESTINAL TRACT PRECANCER
#448Anti-RSPO2 antibodies
#449Anti-RSPO1 antibodies and uses thereof
#450Anti-Trop-2 antibody-drug conjugates and uses thereof
#451Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
#452Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
#453Immunoconjugates with an intracellularly-cleavable linkage
#454Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
#455Anti-LGR5 antibodies and immunoconjugates
#456Assay for colon and other cancers in humans
#457Cancer therapy using CLDN6 target-directed antibodies in vivo
#458Methods for cancer management targeting Co-029
#459Anti-ErbB3 antibodies and uses thereof
#460COLON CANCER TARGETS AND USES THEREOF
#461Antibodies to tumor endothelial marker 7R
#462ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE
#463METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
#464METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION
#465Antibodies to the NOTCH1 receptor
#466TREATMENT WITH ANTI-VEGF ANTIBODIES
#467OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
#468Methods for enhancing anti-tumor antibody therapy
#469Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
#470Endoglin antibodies
#471Antibodies reactive with B7-H3 and uses thereof
#472Methods of treatment by administering antibodies to notch receptors
#473Genetic products differentially expressed in tumors and the use thereof
#474PODXL protein in colorectal cancer
#475Monoclonal antibodies against claudin-18 for treatment of cancer
#476Monoclonal antibodies against claudin-18 for treatment of cancer
#477VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE THREATMENT OF EARLY STAGE TUMORS
#478Prodefensin-A6 assay method for the in vitro diagnosis of colorectal cancer
#479Cancer specific antibody and cell surface proteins
#480Anti-CK8 antibodies to be used for treating colorectal cancers and identifying metastatic and/or invasive phenotypes
#481METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER
#482Antibody having anti-cancer activity
#483Antibodies for epidermal growth factor receptor 3 (HER3)
#484Ang-2 Binding Complexes and Uses Thereof
#485CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH
#486Immunoconjugates with an intracellularly-cleavable linkage
#487CASB7439 constructs
#488Therapeutic and diagnostic conjugates for use with multispecific antibodies
#489Non-functional P2Xreceptor
#490PTA089 PROTEIN
#491TUMOR MARKERS AND METHODS OF USE THEREOF
#492Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
#493Targeting of podoplanin with lectin for use in the prevention and treatment of cancer
#494Methods of enhancing antibody-dependent cellular cytotoxicity
#495Elimination of heterogeneous or mixed cell population in tumors
#496Methods and compositions for diagnosis and treatment of cancer
#497NOTCH1 receptor antibodies and methods of treatment
#498COLON CANCER TARGETS AND USES THEREOF
#499Immunoconjugates with an intracellularly-cleavable linkage
#500Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
#501Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin
#502Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies
#503Method of treating cancer using antibodies to a non-ligand binding region of NOTCH2
#504Methods for treating colorectal cancer
#505Humanized monoclonal antibodies and methods of use
#506Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#507Survivin, a protein that inhibits cellular apoptosis, and its modulation
#508Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#509TREATMENT WITH ANTI-VEGF ANTIBODIES
#510Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
#511Non-functional P2Xreceptor
#512Method of treating solid cancers with pegylated IL-10
#513COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN
#514Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#515DKK1 oncogene as therapeutic target for cancer and a diagnosing marker
#516Endoglin antibodies
#517Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
#518VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS
#519USE OF THERAPEUTIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCER
#520Methods of treating acute myeloid leukemia by blocking CD47
#521SELECTIN LIGANDS USEFUL IN THE DIAGNOSIS AND TREATMENT OF CANCER
#522Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
#523NEOPLASM SPECIFIC ANTIBODIES AND USES THEREOF
#524Compositions and methods for diagnosing and treating cancer
#525Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#526Variants of humanized anti-carcinoma MAb CC49
#527Genes and polypeptides relating to hepatocellular or colorectal carcinoma
#528Cancer associated glucose transporter 8 variant
#529ANTIBODY RECOGNIZING ANTIGEN
#530Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
#531TREATMENT WITH ANTI-VEGF ANTIBODIES
#532APCDD1 inhibitors for treating, diagnosing or detecting cancer
#533Anti-PD-L1 antibodies, compositions and articles of manufacture
#534HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES
#535Monoclonal antibodies against claudin-18 for treatment of cancer
#536Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
#537Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies
#538Chimeric, human and humanized anti-CSAP monoclonal antibodies
#539Production and use of novel peptide-based agents for use with bi-specific antibodies
#540ANTIBODIES RECOGNIZING OXYGEN-REGULATED PROTEIN 150 EXPRESSED ON CANCER CELLS AND METHODS OF USING SAME
#541Antibodies Against Cancer
#542Antibodies to notch receptors
#543Antibodies against RAMP3
#544Immunoconjugates with an intracellularly-cleavable linkage
#545ANTIBODIES AGAINST A PROTEIN ENTITLED 161P2F10B
#546PROTEINS
#547PROTEINS
#548Protein
#549HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES
#550DIAGNOSTIC AGENT FOR TUMOR
#551COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN
#552Cancerous Disease Modifying Antibodies
#553Production and use of novel peptide-based agents with bispecific antibodies
#554CLN248 Antibody Compositions and Methods of Use
#555TREATMENT WITH ANTI-VEGF ANTIBODIES
#556Production and use of novel peptide-based agents for use with bi-specific antibodies
#557Cancer biomarker genes and gene products and methods for using the same
#558Four-jointed box (FJX1) in cancer diagnosis and treatment
#559Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
#560Colon cancer related gene TOM34
#561USE OF PEGYLATED IL-10 TO TREAT CANCER
#562Genetic products differentially expressed in tumors and the use thereof
#563Antibody-drug conjugates and methods
#564Non-functional P2Xreceptor
#565Treatment with anti-VEGF Antibodies
#566Monoclonal antibodies against claudin-18 for treatment of cancer
#567Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#568Genetic products differentially expressed in tumors and the use of thereof
#569Antibodies Against Cancer
#570USE OF BAT MONOCLONAL ANTIBODY FOR IMMUNOTHERAPY
#571CANCEROUS DISEASE MODIFYING ANTIBODIES
#572Cytotoxicity mediation of cells evidencing surface expression of MCSP
#573Elimination of heterogeneous or mixed cell population in tumors
#574Treatment with Anti-VEGF Antibodies
#575Cytotoxicity mediation of cells evidencing surface expression of CD63
#576TREATMENT WITH ANTI-VEGF ANTIBODIES
#577TREATMENT WITH ANTI-VEGF ANTIBODIES
#578Production and use of novel peptide-based agents for use with bi-specific antibodies
#579TREATMENT WITH ANTI-VEGF ANTIBODIES
#580TREATMENT WITH ANTI-VEGF ANTIBODIES
#581Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
#582Host Cells Containing Multiple Integrating Vectors
#583Treatment With Anti-VEGF Antibodies
#584Cancerous disease modifying antibodies
#585TREATMENT WITH ANTI-VEGF ANTIBODIES
#586Cytotoxicity mediation of cells evidencing surface expression of MCSP
#587TREATMENT WITH ANTI-VEGF ANTIBODIES
#588TREATMENT WITH ANTI-VEGF ANTIBODIES
#589VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
#590TREATMENT WITH ANTI-VEGF ANTIBODIES
#591Anti-PRL-3 antibodies and methods of use thereof
#592COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN
#593Cancerous disease modifying antibodies
#594Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#595Method for inducing immune response to NY-CO-58
#596Therapeutic Compositions that alter the immune response
#597Chimeric, human and humanized anti-CSAp monoclonal antibodies
#598Cancerous disease modifying antibodies
#599GENES AND POLYPEPTIDES RELATING TO HEPATOCELLULAR OR COLORECTAL CARCINOMA
#600Chimeric, human and humanized anti-CSAP monoclonal antibodies